Live news related to ARGENX SE stock (NL0010832176): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The immunology group has initiated the acquisition procedure for Forte Biosciences shares at a price of $77 per share, with a deadline set for August …
Argenx released its significantly improved results for the first half of the year on July 23, 2026. Operating revenues reached $2.85 billion, up from …
The Belgian immunology group's stock reaches a new all-time high during the session and continues its upward trajectory that began in the spring. Brea…
Argenx, an immunology specialist, is hosting a webinar today dedicated to its research and development in autoimmune myositis. The event brings togeth…
On Wednesday, Argenx will present long-term efficacy data for its immunosuppressant efgartigimod in two rheumatic autoimmune diseases, myositis and Sj…
Argenx announced on Thursday the organization of a webinar dedicated to its research and development in myositis, an autoimmune rheumatic disease. Thi…
Belgian biotech company Argenx announced on Wednesday its participation in two major investor conferences in the United States in June. Members of its…
Argenx announced on Friday that the U.S. FDA has approved an expanded indication for Vyvgart and Vyvgart Hytrulo, making them the first and only appro…
Argenx released its Q1 2026 results on Thursday, showing a net profit of $366 million, up from $169 million a year earlier, a 116% increase. Basic ear…
Argenx has announced the appointment of Karen Massey as CEO by the board of directors, following shareholder approval of her addition to the board.
